ID   Kasumi-3
AC   CVCL_0612
SY   KASUMI-3; Kasumi 3; Kasumi3; KASUMI3
DR   CLO; CLO_0007070
DR   ATCC; CRL-2725
DR   BioSample; SAMN01821573
DR   BioSample; SAMN01821689
DR   BioSample; SAMN03471777
DR   BioSample; SAMN03472527
DR   BioSample; SAMN03473397
DR   Cosmic; 787442
DR   Cosmic; 975259
DR   Cosmic; 996310
DR   Cosmic; 1037659
DR   Cosmic; 2089647
DR   Cosmic; 2750860
DR   DSMZ; ACC-714
DR   DSMZCellDive; ACC-714
DR   GDSC; 1327776
DR   GEO; GSM1374591
DR   GEO; GSM4254131
DR   JCRB; JCRB1004
DR   JCRB; NIHS0236
DR   PharmacoDB; Kasumi3_735_2019
DR   Wikidata; Q54899520
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8613429;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=14504097;
RX   PubMed=23955599;
RX   PubMed=28196595;
RX   PubMed=32180206;
WW   https://web.archive.org/web/20201109215324/www.infarktforschung.de/macrophages_cell_lines.html
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 55-60 hours (PubMed=8613429); ~3-4 days (DSMZ=ACC-714).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Misspelling: Kusami-3; Cosmic=2750860.
CC   Discontinued: JCRB; NIHS0236; true.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: Myeloblast; CL=CL_0000835.
ST   Source(s): ATCC; DSMZ; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 9,11 (ATCC; JCRB)
ST   D16S539: 11 (DSMZ)
ST   D18S51: 14,17
ST   D19S433: 14,15
ST   D21S11: 30
ST   D2S1338: 18,26
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 20,24
ST   Penta D: 9,11
ST   Penta E: 16
ST   TH01: 6,9 (DSMZ; JCRB)
ST   TH01: 6,9,11 (ATCC)
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C8303; Adult acute myeloid leukemia with minimal differentiation
DI   ORDO; Orphanet_98832; Acute myeloid leukemia with minimal differentiation
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8613429; DOI=10.1111/j.1349-7006.1996.tb00216.x;
RA   Asou H., Suzukawa K., Kita K., Nakase K., Ueda H., Morishita K.,
RA   Kamada N.;
RT   "Establishment of an undifferentiated leukemia cell line (Kasumi-3)
RT   with t(3;7)(q27;q22) and activation of the EVI1 gene.";
RL   Jpn. J. Cancer Res. 87:269-274(1996).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K.-i., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=32180206; DOI=10.1007/s13577-020-00347-5;
RA   Kasai F., Asou H., Ozawa M., Kobayashi K., Kuramitsu H., Satoh M.,
RA   Kohara A., Kaneko Y., Kawamura M.;
RT   "Kasumi leukemia cell lines: characterization of tumor genomes with
RT   ethnic origin and scales of genomic alterations.";
RL   Hum. Cell 33:868-876(2020).
//